On Friday, Gilead Sciences, Inc. (NASDAQ:GILD)’s shares inclined 0.15% to $102.06.
Gilead Sciences, Inc. (GILD) declared that a Phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection met its primary objective. The ongoing study was designed to explore the efficacy and safety of F/TAF-based regimens among virologically suppressed adult patients switching from HIV treatment regimens containing emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (Truvada®). At Week 48, the F/TAF-based regimens and the TDF-based regimens achieved similar rates of virologic suppression based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL (94.3 percent for F/TAF-based regimens as compared to 93.0 percent for TDF-based regimens; difference in percentages: 1.3 percent, 95 percent CI: -2.5 percent to 5.1 percent).
Contrast to the TDF-based regimens, the F/TAF-based regimens demonstrated statistically noteworthy differences in mean bone mineral density (BMD) at the hip and spine (p<0.001) and in the median change in estimated glomerular filtration rate (eGFR) (p<0.001). General safety and discontinuation rates due to adverse events were comparable between the two arms. The most commonly stated adverse events comprised of upper respiratory tract infection, diarrhea, nasopharyngitis, headache and bronchitis. Both regimens were generally well tolerated. Gilead plans to submit these data for presentation at a scientific conference in 2016.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Xerox Corp (NYSE:XRX)’s shares dropped -1.02% to $9.90.
Xerox (XRX) and inVentiv Health declared Xerox’s acquisition of inVentiv Patient Access Solutions (iPAS), an inVentiv Health company. The acquisition will expand Xerox’s pharmacy solutions portfolio with an offering to assist pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement hurdles.
iPAS serves as a patient access and reimbursement services hub for more than 17 major pharmaceutical companies. iPAS assists its clients expand sales by identifying uninsured and underinsured patients, and working with them to eliminate financial obstacles to obtaining medications prescribed by physicians. iPAS’ patient advocates investigate and verify benefits on behalf of a patient, and in cases with limited options, arrange for alternative means for the patient to receive the medication.
Xerox Corporation provides business process and document administration solutions worldwide. The company’s Services segment offers various business process outsourcing services, such as customer care, transaction processing, human resources, communication and marketing, and consulting and analytics services, in addition to finance, accounting, and procurement services.
At the end of Friday’s trade, Sprint Corp (NYSE:S)‘s shares dipped -2.80% to $4.95.
Sprint (NYSE:S) declared it will start a four-year commitment of offering free broadband connectivity to the Pomona, Calif., Unified School District to 300 students at the School of Extended Educational Options (SEEO). The high-speed LTE broadband service will assist students stay connected at-home through a Wi-Fi hotspot. The value of Sprint’s service during the term is estimated at $576,000.
Last year, Sprint pledged to provide wireless broadband connectivity for 50,000 low-income K-12 students across the U.S. as part of the White House initiative, ConnectED – a public and private effort to get technology into classrooms and into the hands of teachers and students to assist bridge the “digital divide.” SEEO is one of the first schools to come online with Sprint.
Sprint Corporation, through its auxiliaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company’s Wireless segment offers wireless data communication services, counting mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet administration, dispatch services, and navigation tools; and mobile entertainment applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
